Ethical Issues in Oncology Raised During the COVID-19 Pandemic
ASCO 20 Virtual Education health policy leaders regarding ethical issues that have been raised in oncology during the COVID-19 pandemic.
Related Articles
The Adrenal Permissive HSD3B1 Allele: A Decade-Long Journey from Initial Discovery to Proven Clinical Significance in Prostate Cancer – Nima Sharifi
Alicia Morgans and Nima Sharifi discuss the role of the HSD3B1 gene and its variants in prostate cancer. Dr. Sharifi explains that the adrenal permissive…
APCCC 2024: In Patients with BCR and Positive Lesion(s) in the Pelvis – Stereotactic or Whole Pelvis Radiotherapy?
APCCC 2024 treatment for biochemical recurrence/PSA persistence, stereotactic or whole pelvis radiotherapy for patients with biochemical recurrence, APCCC key questions.
The Role of Gene Therapy in Enhancing Bladder Cancer Patient Outcomes – Mark Tyson
Neal Shore and Mark Tyson discuss advances in non-muscle invasive bladder cancer treatments, particularly for BCG unresponsive patients. They delve into the approval and data…
APCCC 2024: How to Select Patients with Biochemical Relapse in Whom Salvage Radiation Therapy Can Be Postponed?
APCCC 2024, Biochemical Relapse, Salvage Radiation Therapy, androgen deprivation therapy (ADT), biochemical recurrence after radical prostatectomy, Oncotype DX, Prolaris, ProMark, Decipher genomic classifier score, utilization…
APCCC 2024: Are Some Patients with Biochemical Recurrence (After Radiotherapy And/or Radical Prostatectomy) Candidates for Androgen Receptor Antagonist Monotherapy and How to Manage the Systemic Therapy?
APCCC 2024, prostate cancer, prostate cancer biochemical recurrence, Androgen Receptor Antagonist Monotherapy, EMBARK trial, enzalutamide, bicalutamide, leuprolide acetate, Gynecomastia after prostate cancer treatment, antineoplastic therapy,…
APCCC 2024: How to Manage Patients with PSA Persistence Following Radical Prostatectomy?
APCCC 2024 treatment for biochemical recurrence/PSA persistence, Decipher Genomic Classifier, persistent PSA after radical prostatectomy, detectable post-radical prostatectomy PSA.
APCCC 2024: Debate: How to Best Manage a Fit Patient with High-Risk Localised and Locally Advanced Prostate Cancer? Radiation Therapy as Radical Local Treatment (As Part of a Multimodality Approach)
Were you unable to attend APCCC 2024? Get all of the groundbreaking research, new guidelines, and the latest advances in urologic medicine you missed.
APCCC 2024: High-Risk and Locally Advanced Prostate Cancer in the Context of Current Diagnostic and Therapeutic Options – Which Is the Ideal Definition to Use for Clinical Practice?
APCCC 2024, Prostate Cancer, Ten-year prostate cancer-specific survival rates, CALGB 90203 trial, androgen deprivation therapy (ADT), docetaxel, ADT plus docetaxel, PROTEUS trial, apalutamide, ADT plus…
APCCC 2024: Regional Lymph Node Staging for High-Risk and Locally Advanced Prostate Cancer – What Should Be the Standard?
APCCC 2024, locally advanced prostate cancer, extended pelvic lymph node dissection, radical prostatectomy, pN1 disease, ISUP grade group, PSMA-radio guided techniques.
APCCC 2024: Is Digital Rectal Examination for Definition of Local T-Stage Still Appropriate in the Time of MRI and Next-Generation Imaging?
APCCC 2024, Digital Rectal Examination (DRE), Local T-Stage, multi-parametric MRI (mpMRI), PROBASE trial, PRECISION trial, PRIMARY trial, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET),…